A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Immodulon Therapeutics Ltd
ClinicalTrials.gov Identifier:
NCT01559818
First received: March 19, 2012
Last updated: January 28, 2014
Last verified: January 2014
  Purpose

Patients who were previously enrolled in Study IMM-101-001 and who provide informed consent will be eligible to participate in this study.

Once eligibility is confirmed, a full medical history covering the period from their completion of Study IMM-101-001 to date will be taken.

The treatment regimen with IMM-101 will be one dose given every 4 weeks or as close to this interval as permitted due to practical or logistic considerations. The dose interval may be modified at the discretion of the Investigator provided the minimum period between doses in no less than 14 days.

The overall objective is to determine the long term safety profile of IMM-101 administered intradermally for extended use.


Condition Intervention Phase
Melanoma
Biological: IMM-101
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Long Term Follow up Study for Patients With Melanoma Who Were Previously Enrolled in the Phase I Study IMM-101-001

Resource links provided by NLM:


Further study details as provided by Immodulon Therapeutics Ltd:

Primary Outcome Measures:
  • Safety [ Time Frame: 36 months ] [ Designated as safety issue: Yes ]
    Local and systemic toxicities Adverse events


Secondary Outcome Measures:
  • Efficacy [ Time Frame: 36 months ] [ Designated as safety issue: No ]
    Overall survival (OS). Progression-free survival (PFS). Reduction in metastatic disease.

  • Exploratory [ Time Frame: 36 months ] [ Designated as safety issue: No ]

    Blood samples will be collected and sera prepared for analysis of immunological markers and mediators.

    Exploratory endpoints may include a change in one or more markers of immune status based on cellular involvement, function or cytokine/immune mediator production such as, for example, cytokines and antibodies, or any other clinically or immunologically relevant assays that may become pertinent during the course of the clinical trial.



Estimated Enrollment: 12
Study Start Date: February 2012
Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IMM-101 Biological: IMM-101
IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
Other Name: Heat-killed whole cell M. obuense

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient was previously enrolled in Study IMM 101 001
  • Patient gives consent to make their disease and treatment history for the intervening period between their completion of Study IMM-101-001 and enrollment in this study available to the Sponsor
  • Patient gives signed informed consent for participation in the study

Exclusion Criteria:

  • Female patient of child-bearing potential who is not, in the opinion of the Investigator, using an approved method of birth control (e.g., physical barrier [patient and partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device [IUD]).

Those patients that utilise hormonal contraceptives must have used the same method for at least three months before additional barrier contraception (as described above) is discontinued from being used concomitantly with the hormonal contraception.

  • Patient of non-child-bearing potential are defined as having 12 month amenorrhoea or are surgically sterile.
  • Female patient who is pregnant, breast feeding or planning a pregnancy during the course of the study. A pre-treatment urine pregnancy test measuring human chorionic gonadotrophin (hCG) must be negative.
  • Patient is unable or unwilling to comply with the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01559818

Locations
United Kingdom
Advanced Therapy Centre, The London Clinic
London, United Kingdom
Sponsors and Collaborators
Immodulon Therapeutics Ltd
Investigators
Principal Investigator: Angus Dalgleish, Professor St George's, University of London
  More Information

No publications provided

Responsible Party: Immodulon Therapeutics Ltd
ClinicalTrials.gov Identifier: NCT01559818     History of Changes
Other Study ID Numbers: IMM-101-008
Study First Received: March 19, 2012
Last Updated: January 28, 2014
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas

ClinicalTrials.gov processed this record on September 29, 2014